Showing 1 - 3 results of 3 for search 'Matthias Peipp', query time: 0.03s Refine Results
  1. 1
    Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression

    Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression by Oanh T. P. Nguyen, Sandra Lara, Giovanni Ferro, Matthias Peipp, Sandra Kleinau

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers

    Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers by Ammelie Svea Boje, Lukas Pekar, Katharina Koep, Britta Lipinski, Brian Rabinovich, Andreas Evers, Carina Lynn Gehlert, Steffen Krohn, Yanping Xiao, Simon Krah, Rinat Zaynagetdinov, Lars Toleikis, Sven Poetzsch, Matthias Peipp, Stefan Zielonka, Katja Klausz

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition

    Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition by Britta Lipinski, Laura Unmuth, Paul Arras, Stefan Becker, Christina Bauer, Lars Toleikis, Simon Krah, Achim Doerner, Desislava Yanakieva, Ammelie Svea Boje, Katja Klausz, Matthias Peipp, Vanessa Siegmund, Andreas Evers, Harald Kolmar, Lukas Pekar, Stefan Zielonka

    Published 2023-12-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: